Nanobac Pharmaceuticals, Incorporated NNBP

Company Overview

Nanobac Pharmaceuticals, Incorporated (OTC: NNBP) was a small biotechnology company focused on developing therapeutic and diagnostic products related to the “nanobacteria” hypothesis, a controversial theory proposing that microscopic calcifying particles may contribute to human diseases associated with pathological calcification. Public filings and archived company materials indicate that the company’s research efforts centered on conditions such as cardiovascular calcification, kidney stones, and other chronic inflammatory diseases linked to calcium buildup.

The company operated within the broader biotechnology and pharmaceutical research industry, but available public information suggests that it remained in a developmental stage for much of its existence and did not establish large-scale commercial operations or significant recurring revenue streams. Historical disclosures indicate that the company attempted to position itself around proprietary intellectual property tied to nanobacteria detection and treatment technologies. However, scientific acceptance of the underlying theory remained disputed in academic and medical literature, and publicly available information regarding commercial adoption, regulatory approvals, or sustained operating success is limited. Data inconclusive based on available public sources regarding the company’s current operational status and active business activities.